Chemotherapeutic Management of Soft Tissue Sarcoma
- 1 June 2008
- journal article
- review article
- Published by Elsevier in Surgical Clinics of North America
- Vol. 88 (3) , 647-660
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and FutureThe Oncologist, 2007
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysisInternational Journal of Cancer, 2006
- Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic StudyJournal of Clinical Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Interferon γ Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis–Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing’s SarcomaCancer Research, 2004
- Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcomaJournal of Cancer Research and Clinical Oncology, 2004
- A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcomaEuropean Journal of Cancer, 2001
- Vascular Endothelial Growth Factor and Soft Tissue Sarcomas: Tumor Expression Correlates With GradeAnnals of Surgical Oncology, 2001
- DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean Tunicate Ecteinascidia turbinataBiochemistry, 1996